In the first presentation Tangui Maurice, PhD, a member of the Anavex Scientific Advisory Board, demonstrated for the first time the essential role of sigma-1 receptor (S1R) through S1R KO (knock out) on survival and memory in the presence of amyloid. In the transgenic amyloid expressing mouse model Tg2576, where the sigma-1 receptor (S1R) expression is impaired through S1R KO (knock out), at 12 months the survival was reduced by 50% compared to the non-S1R KO Tg2576 model. Apparently the genetic inactivation of the S1R gene worsens amyloid toxicity and has a detrimental impact on survival and also memory impairment. Amyloid is believed to play a key role in the development of the symptoms of Alzheimer's disease (AD). On the other hand, activation of the S1R through treatment with the S1R agonist ANAVEX 2-73 in the Tg2576 model alleviates amyloid toxicity and resulting learning deficits both after one month and two months daily oral treatment, respectively. In addition expression of ROS (reactive oxidative species) as well as plasticity related IEG and transcription factors in the mouse hippocampus were clearly negatively impacted through the S1R KO, however, were significantly improved through ANAVEX 2-73. This confirms that targeting the S1R, a key factor in brain plasticity, may demonstrate neuroprotection in Alzheimer's disease. ANAVEX 2-73 is currently undergoing a Phase 2a trial in Alzheimer's patients.Apparently the genetic inactivation of the S1R gene worsens amyloid toxicity and has a detrimental impact on survival and also memory impairment. Amyloid is believed to play a key role in the development of the symptoms of Alzheimer's disease (AD). On the other hand, activation of the S1R through treatment with the S1R agonist ANAVEX 2-73 in the Tg2576 model alleviates amyloid toxicity and resulting learning deficits both after one month and two months daily oral treatment, respectively. In addition expression of ROS (reactive oxidative species) as well as plast
Now the infirm is claiming to belong to a "firm" Heh,heh!?
You'll never make back all the money you lost on QCOR.
if either the 3 mg or 6 mg dose indicates conclusive efficacy it's major since it doesn't look like they'll be able to use the 10 mg dose.
Or will they be able to use the 10 mg dose?
Buy his book, market strategy based on premarket futures- lose money and be a hoser at the same time
Ohh now I'm angry. At least I have a sack, nuttless. At least I'm not jealous of Cait and her new boobs like you are.
Right and you talked about million dollar trades at 26, 50, right before the buyout. Constant braggin about short trades at the top that day only to see the stock much higher.a day or week later.
This is more to get JONX to short the stock so I can make some real money, but since you guys are still my favorite board check out avxl. (He follows me around because he enjoys punishment.) Science is sound for AVXL compound, all that's left is the clinic. They have whole different mechanism than other ALZ drugs, all have failed their recent trials Pretty large market plus mechanism translates to other diseases. Favorite selling point is they were a failed digital photo company now trying their hand at biotech and medical research. Straight up risk takers only, GOD I love America. Plus they're Greeks which means they at least went to college although who knows if any actually graduated as fraternities don't always emphasize academics.
MNK bores me plus I'm #$%$ because they got QCOR for a cheap price so I stopped following it. Anyone fill me in whether it's worth doing DD at these prices?
It's hard to remember but weren't you leading the charge against the shorters when they switched from trying to take down QCOR to MNK and MNK went down to 55, i think you said you were buying all you could +some options.
You can't be doing all that bad. Better than Jonx?
We'd rather light a candle than have you curse the darkness. You're the only guy on the QCOR board who had so many failed suicide attempts.
You should always take our advice.
Part of the reason is I could see multiple and lengthy delays on the antitrust review considering that there are so many big players.
I found your advice interesting on the mnk buyout of QCOR, noting that you have followed or experienced the spread on many of these buyout mergers.
I want to buy some options on this buyout and was wondering what you feel the timeline will be for the significant dates, When do you think is the latest or earliest they will give a decision on the antitrust? I'm pretty sure they'll ask for more time to review the deal and Hum should go down sharply and shortly. Any general opinions on stock price with the date would be nice. Jan calls or not a good inflection point?
My guess is that Obama wants universal health care so this will get expedited as it is a step in that direction, but it's hard to know the whims of a dictator.Papa Duck isn't always rational.
Yeah, it's going to cause a lot of pain and bankruptcies for the poor. Maybe I don' t understand how well the poor are shielded from making their deductibles, since the primary goal was to steal from the middle class and give some people a total free ride, but 4 to 5k and expanding deductibles will put a lot of households under for the ones not totally shielded or when an instance happens where they aren't shielded. Many won't go to the doctor because they can't meet their deductibles.
Its a horrible law that hurts a hell of a lot of people, benefits the insurance companies and will collapse under its own weight. California is outraged that AET raised rates 20%. Oregon told insurers to raise rates because they knew that they would be on the hook for any amount the insurance companies lost. The rate increases will continue and the Dems may actually suffer a little, but they were smart by changing the law and the dates that would enact the law for most Americans. So in the long run, it will have little effect whether they merge because the law demands too many expensive treatments for favored constituents and will expand to include many more poor and those previously uncoverable.
Before you leave can you give the bull case for HZNP? I have been interested in the stock since 18 but didn't pull the trigger. Obvious my research was inadequate.
The majority have less benefits, higher premiums, sometimes ridiculously higher, huge deductibles, a smaller network sometimes losing their old doctors entirely. It's just a fact rbeard, not anecdotal evidence although it is nice to hear of someone who actually benefited from Ocare without getting huge subsidies. It's why they illegally keep shifting the date for the law affecting the largest population, past where it will have an effect on the 2016 elections. The premiums will keep going up and they will keep expanding the number of sponges.
Pesotrader is right that prices are rising, but it's not a pressure because they illegally shifted the dates to 2016 that would have devastated the Dems.
Notice the 1.96 in the 6mg/kg group. ARIA was high also meaning raising dose past 6mg kg is limited.
A similar relationship was seen on two measures of cognitive function. On the Mini Mental State Examination, a 30-point scale based on a survey, patients in the placebo group worsened by an average of 2.81 points at 52 weeks. Clinical decline on the MMSE in the treatment arms was 2.18 points in the 1 mg/kg, 0.70 in the 3 mg/kg, 1.96 in the 6 mg/kg arm (that’s not in line with the other results) and 0.56 in the 10 mg/kg arm. That was statistically significant for the 3 mg/kg and 10 mg/kg doses, but not for the others.
On the Clinical Dementia Rating-Sum of the Boxes, a 30-point scale, patients in the placebo group worsened by an average of 1.87 points at 54 weeks compared to 1.72 in the 1 mg/kg group, 1.37 in the 3 mg/kg group, 1.11 in the 6 mg/kg group and 0.63 in the 10 mg/kg treatment arm.